Latest & greatest articles for paroxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on paroxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on paroxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for paroxetine

21. Continuing paroxetine treatment reduces recurrence of major depression in the elderly

Continuing paroxetine treatment reduces recurrence of major depression in the elderly Continuing paroxetine treatment reduces recurrence of major depression in the elderly | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing paroxetine treatment reduces recurrence of major depression in the elderly Article Text Therapeutics Continuing paroxetine treatment reduces recurrence of major depression in the elderly Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all

Evidence-Based Mental Health2006

22. Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women

Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Article Text Therapeutics Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Free Pamela Lotke , MD, MPH , Francisco Garcia , MD

Evidence-Based Medicine (Requires free registration)2005

23. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. 15708844 2005 03 04 2005 03 29 2014 06 08 1756-1833 330 7490 2005 Mar 05 BMJ (Clinical research ed.) BMJ Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. 503 To investigate the efficacy of hypericum (...) extract WS 5570 (St John's wort) compared with paroxetine in patients with moderate to severe major depression. Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial. 21 psychiatric primary care practices in Germany. 251 adult outpatients with acute major depression with total score > or = 22 on the 17 item Hamilton depression scale. 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders

BMJ2005 Full Text: Link to full Text with Trip Pro

24. Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome

Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Article Text Economics Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Free Filippo

Evidence-Based Medicine (Requires free registration)2004

25. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care

The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care Romeo R, Patel A, Knapp M, Thomas C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mirtazapine, a noradrenergic and specific serotonergic antidepressant, versus paroxetine, a selective serotonin reuptake inhibitor, for the treatment of patients with depression in primary care. The doses examined were 30 to 45 mg/day mirtazapine and 20 to 30 mg/day paroxetine. Type of intervention Treatment

NHS Economic Evaluation Database.2004

26. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine

Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine Sheehan D V (...) , Eaddy M, Sarnes M, Vishalpura T, Regan T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Paroxetine controlled release (CR) was compared with paroxetine immediate release (IR) in a naturalistic setting. Type of intervention

NHS Economic Evaluation Database.2004

27. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatments for patients with severe irritable bowel syndrome (IBS) were examined. The treatments were psychotherapy (PSY) and antidepressant therapy with paroxetine (PAR; a selective serotonin reuptake inhibitor). PSY consisted of psychodynamic interpersonal therapy. The patients received one long

NHS Economic Evaluation Database.2003

28. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. 12783913 2003 06 04 2003 06 12 2016 10 17 0098-7484 289 21 2003 Jun 04 JAMA JAMA Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. 2827-34 Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective (...) . To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by a general cross-section of menopausal women. Randomized, double-blind, placebo-controlled, parallel group study conducted across 17 US sites, including urban, suburban, and rural clinics. A total of 165 menopausal women aged 18 years or older experiencing at least 2 to 3 daily hot flashes and must have discontinued any hormone replacement therapy for at least 6 weeks

JAMA2003

29. Paroxetine: an update of its use in psychiatric disorders in adults

Paroxetine: an update of its use in psychiatric disorders in adults Paroxetine: an update of its use in psychiatric disorders in adults Paroxetine: an update of its use in psychiatric disorders in adults Wagstaff A J, Cheer S M, Matheson A J, Ormrod D, Goa K L Authors' objectives To undertake a review of the major pharmacological features of paroxetine and its use in the management of depression, obsessive- compulsive disorder (OCD), panic disorder, social anxiety disorder, generalised anxiety (...) disorder (GAD) and post-traumatic stress disorder (PTSD). Searching MEDLINE, EMBASE and AdisBase were searched. The search terms were 'paroxetine' or 'FG 7051' for MEDLINE, 'paroxetine' or 'BRL 29060' or 'FG 7051' for EMBASE, and 'paroxetine' for AdisBase. The searches were last updated on 21 January 2002. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company

DARE.2002

30. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.

Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 11743835 2001 12 17 2002 01 14 2016 10 17 0098-7484 286 23 2001 Dec 19 JAMA JAMA Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 2947-55 Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. To compare the effectiveness of 3 (...) SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Thirty-seven clinics in 2 US primary care research networks. A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193

JAMA2001

31. Paroxetine for the prevention of depression induced by high-dose interferon alfa.

Paroxetine for the prevention of depression induced by high-dose interferon alfa. 11274622 2001 03 16 2001 04 05 2016 11 24 0028-4793 344 13 2001 Mar 29 The New England journal of medicine N. Engl. J. Med. Paroxetine for the prevention of depression induced by high-dose interferon alfa. 961-6 Depression commonly complicates treatment with the cytokine interferon alfa-2b. Laboratory animals pretreated with antidepressants have less severe depression-like symptoms after the administration (...) of a cytokine. We sought to determine whether a similar strategy would be effective in humans. In a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo. The treatment was begun 2 weeks before the initiation of interferon alfa and continued for the first 12 weeks of interferon alfa therapy. During the first 12 weeks of interferon alfa therapy

NEJM2001

32. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.

Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. 9450712 1998 02 05 1998 02 05 2016 10 17 0098-7484 279 4 1998 Jan 28 JAMA JAMA Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. 287-91 Depression and ischemic heart disease often are comorbid conditions and, in patients who have had a myocardial infarction, the presence of depression is associated with increased mortality. Patients with heart disease need (...) a safe and effective treatment for depression. To compare the efficacy, cardiovascular effects, and safety of a specific serotonin reuptake inhibitor, paroxetine, with a tricyclic antidepressant, nortriptyline hydrochloride, in depressed patients with ischemic heart disease. Two-week placebo lead-in followed by a double-blind randomized 6-week medication trial. Research clinics in 4 university centers. Eighty-one outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth

JAMA1998

33. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. 9728642 1998 09 09 1998 09 09 2016 10 17 0098-7484 280 8 1998 Aug 26 JAMA JAMA Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. 708-13 The generalized type of social phobia (social anxiety disorder) is a severe and often disabling form of social anxiety that affects approximately 5% of the general population. Earlier research has (...) shown monoamine oxidase inhibitors or benzodiazepines to be effective in treating this condition, but neither has achieved widespread use. To compare the efficacy of paroxetine, a selective serotonin reuptake inhibitor, with placebo in adults with generalized social phobia. Twelve-week, multicenter, randomized, double-blind trial. Thirteen centers across the United States and 1 in Canada. Between April 13, 1995, and February 28, 1996, 187 persons meeting Diagnostic and Statistical Manual of Mental

JAMA1998

34. Economic evaluation of paroxetine and imipramine in depressed outpatients

Economic evaluation of paroxetine and imipramine in depressed outpatients Economic evaluation of paroxetine and imipramine in depressed outpatients Economic evaluation of paroxetine and imipramine in depressed outpatients Melton S T, Kirkwood C K, Farrar T W, Brink D D, Carroll N V Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Imipramine and paroxetine in treating depression in outpatients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population identified consisted of patients who were prescribed one of the two drugs (paroxetine or imipramine) for the treatment of depression under the care of a psychiatrist. Setting The setting was tertiary care (a hospital

NHS Economic Evaluation Database.1997

35. Cost analysis of paroxetine versus imipramine in major depression

Cost analysis of paroxetine versus imipramine in major depression Cost analysis of paroxetine versus imipramine in major depression Cost analysis of paroxetine versus imipramine in major depression Bentkover J D, Feighner J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Drug treatment for major depression using the selective serotonin reuptake inhibitor (SSRI) paroxetine (30mg/day), versus the tricyclic antidepressant (TCA) imipramine (125mg/day). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with major depressive illness. Setting Primary and secondary care. The economic study was carried out in the United States. Dates to which data relate Effectiveness

NHS Economic Evaluation Database.1995

36. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization

Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Sclar D A, Robison L M, Skaer T L, Galin R S, Legg R F, Nemec N L, Hughes T E, Buesching D P, Morgan M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Selective Serotonin Reuptake Inhibitors (SSRIs) in antidepressant pharmacotherapy; (a) paroxetine, (b)sertraline, and (c) fluoxetine in the treatment of depression. Type of intervention

NHS Economic Evaluation Database.1995

37. Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada

Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada Lapierre Y, Bentkover J, Schainbaum S, Manners S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Paroxetine (selective serotonin reuptake inhibitor) and Imipramine (tricyclic antidepressant). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study modelled individuals with moderate to severe depression. Setting Primary care. The economic study was carried out in Canada. Dates to which data

NHS Economic Evaluation Database.1995

38. Paroxetine

Paroxetine Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents December 1992 Paroxetine United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug Approval Documents by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu@ohsu.edu (...) . Recommended Citation United States. Food and Drug Administration., "Paroxetine" (1992). FDA Drug Approval Documents. 26. http://digitalcommons.ohsu.edu/fdadrug/26STATISTICAL REVIEW' AND EVALUATION D~: SEP I ~:OA #.: 20-031/Drug Class 1-S AppJic:mt: SmithKHne Beecham .I2r.Yg: Pwdll (paroxetine hydrochloride) Indication: depn::ssiol1 Documents Reyiewed: Volumes 1.450 - 1.476. 1.571 - 1.573, and sponsor's response to requested data dated 27 June 1991. McdiCl! Input: The initial clinical reviewer

FDA Drug Approval Documents (via OHSU)1992